TB

Recent weeks have seen a handful of new Tuberculosis (TB) cases reported in states including Maine, North Carolina and California. While TB is rare in the U.S., even a single active case warrants attention. This article provides an overview of what TB is & how it spreads. TB is caused by a bacterium (Mycobacterium tuberculosis) that typically attacks the lungs, forming lesions called “tubercles,” and can destroy lung tissue — severe disease can lead to respiratory failure.

This article reviews key clinical and public health considerations surrounding recent tuberculosis (TB) cases reported in Maine, North Carolina, and California. Although TB remains relatively rare in the United States, it continues to cause more than 1 million deaths annually worldwide and poses ongoing risks, particularly for individuals with weakened immune systems or those who live or work in congregate settings.

This webinar session, Tuberculosis: A Disease Neglected, Misunderstood, but Deadly, provides a comprehensive overview of TB’s microbiology, pathophysiology, and current epidemiology, along with effective strategies for public health prevention and clinical management. Facilitated by Gavin Harris, MD (Emory University), the program features didactic instruction from Marcos C.

his webinar session features a case-based discussion on the management of tuberculosis in alignment with the 2025 ATS/CDC/ERS/IDSA Clinical Practice Guidelines. Lahari Tumuluri, MD (Tulane University), will present two TB cases illustrating the application of these guidelines. Jussi Saukkonen, MD (Boston University), and Charles Daley, MD (National Jewish), will review the guideline development process, supporting evidence, and practical implications for treating drug-sensitive and drug-resistant TB, drawing on real-world clinical experience.

The webinar is to enhance community medical providers’ awareness of latent tuberculosis infection (LTBI). A brief overview of latent tuberculosis vs. active tuberculosis is given along with the most recent numbers of TB cases in NYS and CDC estimates of those with LTBI. It encourages community providers to assess their patients for TB risk factors, then test and treat them for LTBI as indicated.

This webinar recording discusses tests for TB and drug resistance. It also reviews TB screening, diagnosis, treatment monitoring, and more. 

Tuberculosis (TB) remains the world’s deadliest infectious disease and a major treatment challenge, especially in cases resistant to standard therapies. A new AI-powered tool developed by Tufts University researchers, called DECIPHAER (Decoding Cross-Modal Information of Pharmacologies via Autoencoders), seeks to advance TB treatment by elucidating exactly how drugs kill the bacterium at the cellular and molecular levels.

Tuberculosis (TB), a contagious bacterial infection primarily affecting the lungs, remains a health risk in the U.S. Though cases declined for decades, recent increases — including ~10,347 cases in early data from 2024 — suggest testing and treatment of latent TB is needed more than ever.  Testing is crucial both for diagnosing latent TB (where bacteria are present but symptoms are absent) and active TB disease (which is contagious and manifests symptoms).

This report evaluates the current needs, protocols, and promising practices for latent tuberculosis infection (LTBI) and tuberculosis (TB) screening, testing, and treatment among community health centers serving Asian American/Asian (A/AA) and Native Hawaiian/Pacific Islander (NH/PI) populations.

This report summarizes the TB Elimination Alliance's (TEA) activities and outcomes from 2019 to 2024.